A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF RAVULIZUMAB IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)

WCN23-0140
AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
 
Clinical Glomerulonephritis
 
 
 
A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF RAVULIZUMAB IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)
Kateifides, A.(1)*;Garlo, K.(1);Rice, K.(1);Spoerri, N.(1);Najafian, N.(1)
ie: Azwin Z.1, Siti Y.1, John D.2
(1)Alexion Pharmaceuticals, Research And Development-Clinical Development, Boston, United States
https://storage.unitedwebnetwork.com/files/1/f1659e7bfa46ca633e1c592e854a3331.pdf
https://storage.unitedwebnetwork.com/files/1041/cb61f64b165cb50f46f9fc4ffcebf036.mp3
if any